Will Walgreens' health business drive Q3 earnings and cushion the FY outlook?
JHVEPhoto/iStock Editorial via Getty Images


Walgreens Boots (NASDAQ:WBA) is scheduled to announce Q3 earnings results on Thursday, June 30th, before market open.
The consensus EPS Estimate is $0.93 (-32.6% Y/Y) and the consensus Revenue Estimate is $32.23B (-5.3% Y/Y).
Over the last 2 years, WBA has beaten EPS estimates 88% of the time and has beaten revenue estimates 88% of the time.
Over the last 3 months, EPS estimates have seen 1 upward revision and 13 downward. Revenue estimates have seen 3 upward revisions and 7 downward.
Zacks believes that the quarter's top-line growth is also likely to have benefited from the new Walgreens Health business, which brings equitable, personalized, whole-person healthcare to local communities across America.
Amongst concerns are two factors - weak store traffic and supply chain headwinds.
A Trefis team as cited by Forbes believes - company-wide sales are expected to see a mid-single-digit decline Y/Y, partly due to a lower contribution from the Covid-19 vaccine administration.
In its prior earnings report, the company maintained its FY guidance as it sees accelerating growth amid rising healthcare segment sales and building margins.



The company confirmed that the sale of its Boots drugstore chain in the U.K. has been terminated due to the current change in financial markets.
SA Contributor The Value Pendulum recently analyzed that if the Walgreens stock is a buy before upcoming earnings.

Quick look at the ratings of Seeking Alpha vs. Wall Street on WBA: